No, Humacyte does not pay cash dividends to its common shareholders. As an emerging commercial-stage biotechnology enterprise focused entirely on funding ongoing clinical trials, regulatory expansion, and commercial manufacturing growth, the company retains all available financial resources to support business operations rather than distributing earnings to investors.